Details for New Drug Application (NDA): 020705
✉ Email this page to a colleague
The generic ingredient in RESCRIPTOR is delavirdine mesylate. There is one drug master file entry for this compound. Additional details are available on the delavirdine mesylate profile page.
Summary for 020705
| Tradename: | RESCRIPTOR |
| Applicant: | Viiv Hlthcare |
| Ingredient: | delavirdine mesylate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020705
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Apr 4, 1997 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jul 14, 1999 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020705
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | ⤷ Start Trial | ⤷ Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | ⤷ Start Trial | ⤷ Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | ⤷ Start Trial | ⤷ Start Trial |
| Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
